Attovia Therapeutics raises capital in 17 dollar Nasdaq IPO debut
Biopharmaceutical firm Attovia Therapeutics listed on the Nasdaq stock exchange pricing its initial public offering at 17 00 dollars per share to expand clinical development
Attovia Therapeutics, a biopharmaceutical company backed by Qiming Venture Partners, successfully listed on the Nasdaq on August 5, 2026, at a price of $17.00 per share. The company's shares opened at $21.00 per share, with an estimated market capitalization of $904 million. Attovia Therapeutics focuses on developing next-generation biotherapeutics for immune-mediated diseases with significant unmet medical needs.
Their product candidates are discovered using an exclusive worldwide license platform called ATTOBODY, licensed from Alamar Biosciences. The company has three product candidates currently in the pipeline: ATTO-1310, ATTO-2306, and ATTO-1091. Proceeds from this IPO will primarily be used to advance the clinical development of these three candidates and support research pipeline activities.
Dr. Kan Chen, a partner at Qiming Venture Partners, highlighted the importance of Attovia's platform technology for engineering complex multi-specific biologics, and expressed optimism about the company's ability to deliver novel therapeutics to patients globally.
Written by urgent.news from Vietnam Investment Review's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
